MarketScreener.com, stock quotes, stock exchange, market price, stock market advice, technical analysis, stock chart analysis, Company News

Log in

Become a member for free

Become a member for free

Sign up

New member

Sign up for FREE

New customer

Discover our services

English (Canada)

Deutsch (Deutschland)

Deutsch (Schweiz)

Français (France)

Français (Suisse)

Nederlands (Nederland)

Nederlands (België)

MARKETS
- Equities
- United States
- North America
- Europe
- Asia
- Middle East
- More Equities
NEWS
ANALYSIS
STOCK PICKS
- All Stock Picks
PORTFOLIOS
- My Portfolio
- Virtual Portfolios
- MarketScreener Portfolios
- USA Portfolio
- European Portfolio
- Asian Portfolio
WATCHLISTS
RANKINGS
- Top Fundamentals
- Top Capitalization
- Top Yield
- Top PER
- Top Consensus
- Top Fundamentals
- Top ranking ESG
- Top Technicals
- Top RSI
- Unusual volumes
- Top Gaps
- Top STIM
- Breakouts
- Trends
- Top Movers
- Top USA
- Top Canada
- Top U.K.
- Top Germany
- Top Europe
- Top Asia
SCREENERS
- Investment Themes
- Cybersecurity
- Boats
- Europe's family businesses
- The SPAC
- The Golden Age of Video Games
- The future of mobility
- Stock Screener Home
- My Screeners
- All my stocks
- Watchlists
- Virtual Portfolios
TOOLS
- MarketScreener tools
- Stock Screener
- iPhone App
- Expert tools
- Stock Screener PRO
- Portfolio Creator
- Event Screener
OUR SERVICES
- Our Stock Picks
- Thematic Investment Lists
- Stock Screener

NTUS US6390501038

NATUS MEDICAL INCORPORATED

Report

Delayed Nasdaq - 04:00 2022-06-24 pm EDT
32.65	USD		+1.15%

06/15	NATUS MEDICAL INC : Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits (form 8-K)	AQ
05/17	NATUS MEDICAL INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA : Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Natus Medical Incorporated - NTUS	BU
05/06	NATUS MEDICAL INC Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)	AQ

Valuation

Fiscal Period: December

2018

2019

2020

2021

2022

2023

Capitalization¹

1 137

1 115

672

801

1 118

-

Enterprise Value (EV)¹

1 137

1 115

672

801

1 118

1 118

P/E ratio

-49,3x

-78,5x

-40,9x

60,8x

33,0x

25,1x

Yield

-

-

-

-

-

-

Capitalization / Revenue

2,14x

2,25x

1,62x

1,69x

2,26x

2,16x

EV / Revenue

2,14x

2,25x

1,62x

1,69x

2,26x

2,16x

EV / EBITDA

16 194 327x

16 227 899x

-

-

-

-

Price to Book

-

-

-

-

-

-

Nbr of stocks (in thousands)

33 418

33 797

33 528

33 772

34 243

-

Reference price (USD)

34,0

33,0

20,0

23,7

32,7

32,7

Announcement Date

02/13/2019

02/06/2020

02/25/2021

02/24/2022

-

-

¹ USD in Million

Previous period

Next period

Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December

2018

2019

2020

2021

2022

2023

Net sales¹

531

496

416

473

495

517

EBITDA

70,2

68,7

-

-

-

-

Operating profit (EBIT)¹

67,9

60,5

18,6

56,9

65,6

71,9

Operating Margin

12,8%

12,2%

4,47%

12,0%

13,3%

13,9%

Pre-Tax Profit (EBT)

-

-19,7

-

19,4

-

-

Net income¹

-22,9

-14,1

-16,6

13,2

34,0

44,9

Net margin

-4,32%

-2,85%

-4,00%

2,78%

6,87%

8,68%

EPS²

-0,69

-0,42

-0,49

0,39

0,99

1,30

Dividend per Share

-

-

-

-

-

-

Announcement Date

02/13/2019

02/06/2020

02/25/2021

02/24/2022

-

-

¹ USD in Million

² USD

Previous period

Next period

Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December

2021 Q3

2021 Q4

2022 Q1

2022 Q2

2022 Q3

2022 Q4

Net sales¹

114

129

120

120

124

135

EBITDA

-

-

-

-

-

-

Operating profit (EBIT)¹

13,5

21,3

12,8

14,6

16,8

22,0

Operating Margin

11,9%

16,6%

10,7%

12,1%

13,6%

16,3%

Pre-Tax Profit (EBT)

7,50

3,63

-

-

-

-

Net income¹

5,57

1,75

1,90

6,80

9,30

13,9

Net margin

4,89%

1,36%

1,59%

5,65%

7,52%

10,3%

EPS²

0,16

0,05

0,06

0,20

0,27

0,40

Dividend per Share

-

-

-

-

-

-

Announcement Date

11/04/2021

02/24/2022

05/05/2022

-

-

-

¹ USD in Million

² USD

Previous period

Next period

Estimates

Balance Sheet Analysis

Fiscal Period: December

2018

2019

2020

2021

2022

2023

Net Debt

-

-

-

-

-

-

Net Cash position

-

-

-

-

-

-

Leverage (Debt / EBITDA)

-

-

-

-

-

-

Free Cash Flow

-

-

-

-

-

-

ROE (Net Profit / Equities)

-

-

-

-

-

-

Shareholders' equity¹

-

-

-

-

-

-

ROA (Net Profit / Asset)

-

-

-

-

-

-

Assets¹

-

-

-

-

-

-

Book Value Per Share

-

-

-

-

-

-

Cash Flow per Share

-

-

-

-

-

-

Capex

-

-

-

-

-

-

Capex / Sales

-

-

-

-

-

-

Announcement Date

02/13/2019

02/06/2020

02/25/2021

02/24/2022

-

-

¹ USD in Million

Previous period

Next period

Estimates

Key data

Capitalization (USD)	1 118 037 606
Net sales (USD)	473 438 000
Number of employees	1 400
Sales / Employee (USD)	338 170
Free-Float	98,1%
Free-Float capitalization (USD)	1 096 243 961
Avg. Exchange 20 sessions (USD)	12 766 010
Average Daily Capital Traded	1,14%

EPS & Dividend

Year-on-year evolution of the PER